Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cellsSmriti K Raychaudhuri, Christine Abria, Siba P Raychaudhuri
20 December 2019
Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?Antoine Fayand, Veronique Hentgen, Stephanie Ducharme-Bénard, Pierre Quartier, Brigitte Bader-Meunier, Isabelle Koné-Paut, Gilles Grateau, Sophie Georgin-Lavialle
31 December 2019
Response to: ‘NCF1-339 polymorphism and systemic lupus erythematosus’ by Joob and WiwanitkitCarl Petrus Linge, Anders Bengtsson
9 December 2019
Response to: ‘Correspondence to ‘Slope sign’: a feature of large vessel vasculitis?’ by Milchert et alAlwin Sebastian, Abdul Kayani, Bhaskar Dasgupta
11 December 2019
Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et alMartin Aringer, Karen Costenbader, Thomas Dörner, Sindhu R Johnson
20 December 2019
Response to: ‘Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares’ by Didierlaurent et alChio Yokose, Hyon Choi
18 December 2019
Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)Luis Fernando Perez-Garcia, Esther Röder, Robbert J Goekoop, Johanna M W Hazes, Marc R Kok, Hieronymus T W Smeele, Ilja Tchetverikov, Annette H M van der Helm-van Mil, Jos H van der Kaap, Petra Kok, Bouwe P Krijthe, Radboud J E M Dolhain
9 August 2021
Response to: ‘European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view’ by Infantino et alMartin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson
12 December 2019
Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion’ by Sacre et alMartin Aringer, Karen Costenbader, Thomas Dörner, Sindhu R Johnson
20 December 2019
Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al’ by Berkhout et alYoshiya Tanaka, Koji Oba, Tsutomu Takeuchi
9 December 2019
